ACS Medicinal Chemistry Letters
Letter
long-lasting and potent inhibitor of influenza neuraminidase.
ChemBioChem 2012, 13, 2191−5.
REFERENCES
■
(1) Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug
discovery: where do we stand and where do we go? J. Med. Chem.
2010, 53, 521−38.
(2) Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart,
M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.;
Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification
of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381,
661−6.
(3) Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.;
Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J.
P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the
chemokine receptor CC-CKR-5. Nature 1996, 381, 667−73.
(4) Doranz, B. J.; Berson, J. F.; Rucker, J.; Doms, R. W. Chemokine
receptors as fusion cofactors for human immunodeficiency virus type 1
(HIV-1). Immunol. Res. 1997, 16, 15−28.
(5) Broder, C. C.; Collman, R. G. Chemokine receptors and HIV. J.
Leukocyte Biol. 1997, 62, 20−9.
(6) Bredeek, U. F.; Harbour, M. J. CCR5 antagonists in the treatment
of treatment-naive patients infected with CCR5 tropic HIV-1. Eur. J.
Med. Res. 2007, 12, 427−34.
(7) Dorr, P.; Perros, M. CCR5 inhibitors in HIV-1 therapy. Expert
Opin. Drug Discovery 2008, 3, 1345−61.
(8) Latinovic, O.; Kuruppu, J.; Davis, C.; Le, N.; Heredia, A.
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist
Maraviroc. Clin. Med. Ther. 2009, 1, 1497−1510.
(9) Poveda, E.; Paredes, R.; Moreno, S.; Alcami, J.; Cordoba, J.;
Delgado, R.; Gutierrez, F.; Llibre, J. M.; Garcia Deltoro, M.;
Hernandez-Quero, J.; Pulido, F.; Iribarren, J. A.; Garcia, F. Update
on clinical and methodological recommendations for genotypic
determination of HIV tropism to guide the usage of CCR5
antagonists. AIDS Rev. 2012, 14, 208−17.
(19) Sato, S.; Inokuma, T.; Otsubo, N.; Burton, D. R.; Barbas, C. F.,
3rd. Chemically Programmed Antibodies as HIV-1 Attachment
Inhibitors. ACS Med. Chem. Lett. 2013, 4, 460−465.
(20) Wagner, J.; Lerner, R. A.; Barbas, C. F., 3rd Efficient aldolase
catalytic antibodies that use the enamine mechanism of natural
enzymes. Science 1995, 270, 1797−800.
(21) Zhong, G.; Lerner, R. A.; Barbas, I. C. Broadening the Aldolase
Catalytic Antibody Repertoire by Combining Reactive Immunization
and Transition State Theory: New Enantio- and Diastereoselectivities.
Angew. Chem., Int. Ed. Engl. 1999, 38, 3738−3741.
(22) Shabat, D.; Rader, C.; List, B.; Lerner, R. A.; Barbas, C. F., 3rd.
Multiple event activation of a generic prodrug trigger by antibody
catalysis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 6925−30.
(23) Brinckerhoff, L. H.; Kalashnikov, V. V.; Thompson, L. W.;
Yamshchikov, G. V.; Pierce, R. A.; Galavotti, H. S.; Engelhard, V. H.;
Slingluff, C. L., Jr. Terminal modifications inhibit proteolytic
degradation of an immunogenic MART-1(27−35) peptide: implica-
tions for peptide vaccines. Int. J. Cancer 1999, 83, 326−34.
(24) Cheng, T. L.; Chen, B. M.; Chan, L. Y.; Wu, P. Y.; Chern, J. W.;
Roffler, S. R. Poly(ethylene glycol) modification of beta-glucuronidase-
antibody conjugates for solid-tumor therapy by targeted activation of
glucuronide prodrugs. Cancer Immunol. Immunother. 1997, 44, 305−
15.
(25) Chaffee, S.; Mary, A.; Stiehm, E. R.; Girault, D.; Fischer, A.;
Hershfield, M. S. IgG antibody response to polyethylene glycol-
modified adenosine deaminase in patients with adenosine deaminase
deficiency. J. Clin. Invest. 1992, 89, 1643−51.
(26) Wang, Y. S.; Youngster, S.; Grace, M.; Bausch, J.; Bordens, R.;
Wyss, D. F. Structural and biological characterization of pegylated
recombinant interferon alpha-2b and its therapeutic implications. Adv.
Drug Delivery Rev. 2002, 54, 547−70.
(27) Greenwald, R. B.; Pendri, A.; Conover, C.; Gilbert, C.; Yang, R.;
Xia, J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene
glycol) ester transport forms. J. Med. Chem. 1996, 39, 1938−40.
(28) Pepinsky, R. B.; Lee, W. C.; Cornebise, M.; Gill, A.; Wortham,
K.; Chen, L. L.; Leone, D. R.; Giza, K.; Dolinski, B. M.; Perper, S.;
Nickerson-Nutter, C.; Lepage, D.; Chakraborty, A.; Whalley, E. T.;
Petter, R. C.; Adams, S. P.; Lobb, R. R.; Scott, D. M. Design, synthesis,
and analysis of a polyethelene glycol-modified (PEGylated) small
molecule inhibitor of integrin {alpha}4{beta}1 with improved
pharmaceutical properties. J. Pharmacol. Exp. Ther. 2005, 312, 742−50.
(29) Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.;
Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with
major classes of small-molecule anti-HIV CCR5 antagonists. Mol.
Pharmacol. 2008, 73, 789−800.
(10) Reshef, R.; Luger, S. M.; Hexner, E. O.; Loren, A. W.; Frey, N.
V.; Nasta, S. D.; Goldstein, S. C.; Stadtmauer, E. A.; Smith, J.; Bailey,
S.; Mick, R.; Heitjan, D. F.; Emerson, S. G.; Hoxie, J. A.; Vonderheide,
R. H.; Porter, D. L. Blockade of lymphocyte chemotaxis in visceral
graft-versus-host disease. N. Engl. J. Med. 2012, 367, 135−45.
(11) Alonzo, F., 3rd; Kozhaya, L.; Rawlings, S. A.; Reyes-Robles, T.;
DuMont, A. L.; Myszka, D. G.; Landau, N. R.; Unutmaz, D.; Torres, V.
J. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature
2013, 493, 51−5.
(12) Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F.,
3rd Chemically programmed monoclonal antibodies for cancer
therapy: adaptor immunotherapy based on a covalent antibody
catalyst. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 5396−400.
(13) Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F.,
3rd. Small molecule drug activity in melanoma models may be
dramatically enhanced with an antibody effector. Int. J. Cancer 2006,
119, 1194−207.
(14) Gavrilyuk, J. I.; Wuellner, U.; Barbas, C. F., 3rd Beta-lactam-
based approach for the chemical programming of aldolase antibody
38C2. Bioorg. Med. Chem. Lett. 2009, 19, 1421−4.
(15) Wuellner, U.; Gavrilyuk, J. I.; Barbas, C. F., 3rd Expanding the
concept of chemically programmable antibodies to RNA aptamers:
chemically programmed biotherapeutics. Angew. Chem., Int. Ed. Engl.
2010, 49, 5934−7.
(16) Gavrilyuk, J.; Uehara, H.; Otsubo, N.; Hessell, A.; Burton, D. R.;
Barbas, C. F., 3rd Potent inhibition of HIV-1 entry with a chemically
programmed antibody aided by an efficient organocatalytic synthesis.
ChemBioChem 2010, 11, 2113−8.
(30) Sinha, S. C.; Das, S.; Li, L. S.; Lerner, R. A.; Barbas, C. F., 3rd.
Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Nat. Protoc. 2007, 2, 449−56.
(31) Wood, A.; Armour, D. The discovery of the CCR5 receptor
antagonist, UK-427,857, a new agent for the treatment of HIV
infection and AIDS. Prog. Med. Chem. 2005, 43, 239−71.
(32) Yamaoka, T.; Tabata, Y.; Ikada, Y. Distribution and tissue uptake
of poly(ethylene glycol) with different molecular weights after
intravenous administration to mice. J. Pharm. Sci. 1994, 83, 601−6.
(33) Bailon, P. B. W. Polyethylene glycol-conjugated pharmaceutical
proteins. Pharm. Sci. Technol. Today 1998, 1, 352−356.
(34) Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-
based tumor targeting. Cancer Biother. Radiopharm. 2009, 24, 155−61.
(35) Popkov, M.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., 3rd.
Instant immunity through chemically programmable vaccination and
covalent self-assembly. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 4378−
83.
(36) Gavrilyuk, J.; Ban, H.; Uehara, H.; Sirk, S. J.; Saye-Francisco, K.;
Cuevas, A.; Zablowsky, E.; Oza, A.; Seaman, M. S.; Burton, D. R.;
Barbas, C. F., 3rd. Antibody conjugation approach enhances breadth
and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.
J. Virol. 2013, 87, 4985−93.
(17) Huang, H.; Lai, J. Y.; Do, J.; Liu, D.; Li, L.; Del Rosario, J.;
Doppalapudi, V. R.; Pirie-Shepherd, S.; Levin, N.; Bradshaw, C.;
Woodnutt, G.; Lappe, R.; Bhat, A. Specifically targeting angiopoietin-2
inhibits angiogenesis, Tie2-expressing monocyte infiltration, and
tumor growth. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011,
17, 1001−11.
(18) Hayakawa, M.; Toda, N.; Carrillo, N.; Thornburg, N. J.; Crowe,
J. E., Jr.; Barbas, C. F., 3rd A chemically programmed antibody is a
E
dx.doi.org/10.1021/ml400370w | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX